Innocare Pharma Limited (688428.SH) announced that its self-developed BTK inhibitor, orelabrutinib, has met the primary endpoint in a Phase IIb clinical study for treating systemic lupus erythematosus (SLE). The study has also received approval from China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to proceed with Phase III registrational clinical trials. The company plans to initiate the trial promptly. Results from the Phase IIb study demonstrated that orelabrutinib exhibited outstanding efficacy, favorable tolerability, and safety in patients treated for 48 weeks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments